Cargando…

Host-pathogen interactome mapping for HTLV-1 and -2 retroviruses

BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) and type 2 both target T lymphocytes, yet induce radically different phenotypic outcomes. HTLV-1 is a causative agent of Adult T-cell leukemia (ATL), whereas HTLV-2, highly similar to HTLV-1, causes no known overt disease. HTLV gene products ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonis, Nicolas, Rual, Jean-François, Lemmens, Irma, Boxus, Mathieu, Hirozane-Kishikawa, Tomoko, Gatot, Jean-Stéphane, Dricot, Amélie, Hao, Tong, Vertommen, Didier, Legros, Sébastien, Daakour, Sarah, Klitgord, Niels, Martin, Maud, Willaert, Jean-François, Dequiedt, Franck, Navratil, Vincent, Cusick, Michael E, Burny, Arsène, Van Lint, Carine, Hill, David E, Tavernier, Jan, Kettmann, Richard, Vidal, Marc, Twizere, Jean-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351729/
https://www.ncbi.nlm.nih.gov/pubmed/22458338
http://dx.doi.org/10.1186/1742-4690-9-26
Descripción
Sumario:BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) and type 2 both target T lymphocytes, yet induce radically different phenotypic outcomes. HTLV-1 is a causative agent of Adult T-cell leukemia (ATL), whereas HTLV-2, highly similar to HTLV-1, causes no known overt disease. HTLV gene products are engaged in a dynamic struggle of activating and antagonistic interactions with host cells. Investigations focused on one or a few genes have identified several human factors interacting with HTLV viral proteins. Most of the available interaction data concern the highly investigated HTLV-1 Tax protein. Identifying shared and distinct host-pathogen protein interaction profiles for these two viruses would enlighten how they exploit distinctive or common strategies to subvert cellular pathways toward disease progression. RESULTS: We employ a scalable methodology for the systematic mapping and comparison of pathogen-host protein interactions that includes stringent yeast two-hybrid screening and systematic retest, as well as two independent validations through an additional protein interaction detection method and a functional transactivation assay. The final data set contained 166 interactions between 10 viral proteins and 122 human proteins. Among the 166 interactions identified, 87 and 79 involved HTLV-1 and HTLV-2 -encoded proteins, respectively. Targets for HTLV-1 and HTLV-2 proteins implicate a diverse set of cellular processes including the ubiquitin-proteasome system, the apoptosis, different cancer pathways and the Notch signaling pathway. CONCLUSIONS: This study constitutes a first pass, with homogeneous data, at comparative analysis of host targets for HTLV-1 and -2 retroviruses, complements currently existing data for formulation of systems biology models of retroviral induced diseases and presents new insights on biological pathways involved in retroviral infection.